SUBSCRIBE
SUBSCRIBE
News   Drug Development

Pfizer Inc. Reports Promising Phase II Data On Lung Cancer Drug, PF-00299804

October 12, 2010 | 
1 min read
Pharma Times -- Pfizer’s investigational agent PF-00299804 has shown an ability to prevent disease progression when given as a first-line treatment in patients with advanced non-small cell lung cancer.
Clinical research Phase 2
Pfizer
MORE ON THIS TOPIC
Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.
Cardiovascular disease
Gossamer Nosedives as Late-Stage Failure Plunges PAH Program Into Uncertainty
February 24, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of man walking in the beach between two blue seas, surreal abstract path concept
Rare disease
FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases
February 23, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Concept of saving money with a pink colored piggy bank held in a hand in front of a blackboard with hand drawn coins
Weight loss
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test
February 23, 2026
 · 
4 min read
 · 
Annalee Armstrong
Insights
Historic ALS Investment Signals New Treatment Momentum
February 23, 2026
 · 
3 min read
 · 
Jennifer Smith-Parker